Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02632448 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
A Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by Esperas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 229
- Enrollment target
- 16
- Study locations
NCT02632448: Completed Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by Esperas Pharma.
NCT02632448 is a Phase 1 study of Breast Cancer and Colorectal Cancer that has completed, run by Esperas Pharma. The registered enrollment target is 229 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 16 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02632448, a Phase 1 study of Breast Cancer and Colorectal Cancer, has completed, sponsored by Esperas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 229 participants
- Enrollment target
- 16
- Study locations
Study Summary
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG LY2880070
Study Locations (16)
Other
- General Hospital Zadar - Zadar
- University Hospital Centre Zagreb - Zagreb
- Centrum Onkologii im. prof. F. Łukaszczyka - Bydgoszcz
- Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz - Gdansk
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o. o. - Krakow
- Szpital Specjalistyczny im. L. Rydygiera w Krakowie sp. z o. o. - Krakow
Quebec
- Centre Hospitalier de l'Université de Montréal - Montreal
- Jewish General Hospital - Montreal
- McGill University Health Centre - Montreal
Alberta
- Tom Baker Cancer Centre - Calgary
- Cross Cancer Institute - Edmonton
Ontario
- Ottawa Hospital Cancer Centre - Ottawa
- University Health Network - Princess Margaret Hospital - Toronto
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
British Columbia
- BC Cancer Agency - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2016-05-16 |
| Est. Completion | 2025-04-14 |
| Phase | Phase 1 |
What the finished NCT02632448 record still lists
NCT02632448 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT02632448 lists 16 locations in 7 states (Other, Quebec, Alberta).
Frequently Asked Questions
What is clinical trial NCT02632448 about?
NCT02632448 is a clinical study titled "A Study of LY2880070 in Participants With Advanced or Metastatic Cancer". The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
What is the current status of trial NCT02632448?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 229 participants. The study started on 2016-05-16. Estimated completion is 2025-04-14.
What conditions does trial NCT02632448 study?
This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Endometrial Cancer, Neoplasms.
What interventions are being tested in trial NCT02632448?
The interventions under investigation include: Gemcitabine (DRUG), LY2880070 (DRUG).
Who is sponsoring clinical trial NCT02632448?
This trial is sponsored by Esperas Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02632448 being conducted?
This trial has 16 study locations across Massachusetts, Michigan, Alberta, British Columbia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02632448's enrollment target sits among peer trials
229 338th of 1224 higher than 886 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI